Case report: Pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor

Case report: Pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor

BackgroundModern chemotherapeutic agents continue to evolve as modern monoclonal antibody treatments are designed to directly target proteins, enzymes, and focal loci. A particular class of these medications, fibroblast growth factor (FGFR) inhibitors, specifically pemigatinib (Pemazyre®; Incyte), h...

Full description

Bibliographic Details
Main Authors: Daniel Barmas-Alamdari, George Jiao, Ronni Lieberman
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Ophthalmology
Subjects:
pemigatinib
subretinal fluid
FGFR (fibroblast growth factor receptor)
FGFR inhibitor
pigment epithelial detachment
Pemazyre
Online Access:https://www.frontiersin.org/articles/10.3389/fopht.2023.1247296/full

Internet

https://www.frontiersin.org/articles/10.3389/fopht.2023.1247296/full

Similar Items